[1] S. Lapointe, A. Perry, N. A. Butowski (2018) Primary brain tumours in adults. Lancet 392:432-446.
[2] RP. Deshpande, Y. Chandra Sekhar, M. Pan, PP. Babu (2017) SIRP alpha protein downregulates in human astrocytoma: presumptive involvement of HsamiR-520d-5p and Hsa-miR-520d-3p. Mol Neurobiol 54:8162–8169.
[3] P. Castel, A. Cheng, A. Navarro,D. Everman, A. Papageorge, D. Simanshu, A. Tankka, J. Gale as, A. Urisman, F. M. Cormick (2015) RIT1 oncoproteins escape LZTR1-mediated proteolysis. Science 363:1226-1230
[4] S. Mir, W.k. Cai, D. A. Andres ( 2017) RIT1 GTPase Regulates Sox2 Transcriptional Activity and Hippocampal Neurogenesis. J Biol Chem 292:2054-2064.
[5] W.k.Cai,J.L. Rudolph, T. Sengoku, D.A. An (2012) Rit GTPase regulates a p38 MAPK-dependent neuronal survival pathway. Neurosci Lett 53:1125-30.
[6] F.J. Xu, S.A. Sun, S.L. Y. Guo, M. Dai, Y.C. Teng (2015) Elevated expression of RIT1 correlates with poor prognosis in endometrial cance. Int J Clin Exp Pathol 8:10315-24.
[7] H. Cavé,2, A. Cay. Ghedira, Y.L. Capri, N. Pouvreau, N. Fillot, A. Trimouille, C. Vignal, O. Fenneteau, Y. Alembik, J.L. Alessandri, P. Blanchet, O. Boute, P. Bouvagnet, ect (2016) Mutations in RIT1 cause Noonan syndrome with possible juvenile myelomonocytic leukemia but are not involved in acute lymphoblastic leukemia. Eur J Hum Genet 24:1124-31.
[8] A.H. Berger, M. Imielinski, F. Duk.Wala, N. Kan, G.X. Shi, D.A. Andres and M. Meyerson (2014) Oncogenic RIT1 mutations in lung adenocarcinoma. Oncogene 33:4418-23.
[9] Z.Song, T.F. Liu, J. Chen, C. Ge, F. Zhao, M. Zhu, T. Chen, Y. Cui, H. Tian, M. Yao, J.J. Li (2019) HIF-1α-induced RIT1 promotes liver cancer growth and metastasis and its deficiency increases sensitivity to sorafenib. Cancer Lett 28: 96-107.
[10] Y.F. Feng, Y.Y. Lei, J.B. Lu, S.Y. Xi, Y. Zhang, Huang, Wu and F. Wang (2018) RIT1 suppresses esophageal squamous cell carcinoma growth and metastasis and predicts good prognosis. Cell Death Dis 9:1085.
[11] Viatour P, Merville MP, Bours V, Chariot A (2005) Phosphorylation of NF-kappaB and IkappaB proteins: implications in cancer and inflammation. Trends Biochem Sci 30:43-52.
[12] Gutierrez H, Davies AM (2001) Regulation of neural process growth, elaboration and structural plasticity by NF-κB. Trends Neurosci 34:316-325.
[13] Hoesel B, Schmid JA (2013) The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer 12:86.
[14] Dolcet X, Llobet D, Pallares J, Matias-Guiu X (2005) NF-kB in development and progression of human cancer. Virchows Arch 446:475-482.
[15] Taniguchi K, Karin M (2018) NF-κB, inflammation, immunity and cancer: coming of age. Nat Rev Immunol 18:309-324.
[16] Chen J, Yang X, Liu R, C, Wang H, Huang L et al (2020) Circular RNA GLIS2 promotes colorectal cancer cell motility via activation of the NF-κB pathway. Cell Death Dis 11:788.
[17] Zhang Y, Zhou X, Zhang M, Cheng L, Zhang Y, WaX (2019) ZBTB20 promotes cell migration and invasion of gastric cancer by inhibiting IκBα to induce NF-κB activation. Artif Cells Nanomed Biotechnol 47:3862-3872.
[18] Li Y, Deng L, Zhao X, Li B, Ren D (2018) Tripartite motif-containing 37 (TRIM37) promotes the aggressiveness of non-small-cell lung cancer cells by activating the NF-κB pathway. J Pathol. 246:366-378.
[19] Li Y, He LR, Gao Y, Zhou NN, Liu Y, Zhou (2019) CHD1L contributes to cisplatin resistance by upregulating the ABCB1-NF-κB axis in human non-small-cell lung cancer. Cell Death Dis 10:99.
[20] Liang S, Chen Z, Jiang G, Zhou Y, Li et al (2017) Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-κB/IL-6 signals. Cancer Lett. 386:12-23.
[21] Nakshatri H, Goulet RJ, Jr (2002) NF-kappaB and breast cancer. Curr Probl Cancer 26:282-309.
[22] Gray GK, McFarland BC, Nozell SE, Benveniste EN (2014) NF-κB and STAT3 in glioblastoma: therapeutic targets coming of age. Expert Rev Neurother 14:1293-1306.